1. Home
  2. Companies
  3. PAB
  4. Material Events

Patrys (ASX:PAB) — Material Events

ASX:PAB · 16 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Significant 10 articles Notable 6 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
10
Patrys Acquires Reliis to Fast-Track Injectable Delirium TreatmentMedium
Patrys acquires Reliis to advance injectable quetiapine for delirium treatment with fast-track FDA pathway
28 Jan 2026 ·Acquisition Announcement / Investor Presentation ·85
Patrys Acquires Injectable Antipsychotic to Target $2B Delirium MarketMedium
Patrys Acquires Reliis to Expand Pipeline with Injectable Antipsychotic Targeting $2B Delirium Market
26 Nov 2025 ·Acquisition Announcement ·85
Patrys Bolsters Pipeline with Reliis Acquisition and CNS Therapeutics PushMedium
Patrys acquires Reliis, expands CNS therapeutics pipeline with near-term clinical milestones
30 Jan 2026 ·Quarterly Activities Report and Appendix 4C ·80
Patrys Unveils Injectable Quetiapine for $2B Delirium Market with Fast FDA TrackMedium
Patrys advances injectable quetiapine reformulation for delirium with accelerated FDA pathway and strong market potential
31 Mar 2026 ·Investor Presentation ·80
Patrys Expands Pipeline with Reliis Acquisition and New Board AppointmentsMedium
Patrys completes Reliis acquisition, adds injectable quetiapine program, appoints two new directors
28 Jan 2026 ·Acquisition Completion and Board Appointment ·80
Patrys Doubles Loss Amid Strategic Acquisition and Pipeline ShiftMedium
Patrys reports widened half-year loss, acquires Reliis, advances dual-platform biotech strategy
26 Feb 2026 ·Appendix 4D Half-year report ·75
Patrys Locks in 50% Revenue Share on Deoxymab IP with Yale DealMedium
Patrys Secures 50% Revenue Share in Deoxymab IP Commercialisation Deal with Yale University
13 July 2026 ·Commercialisation Agreement ·75
Patrys Secures A$3.2 Million to Propel Injectable Quetiapine TrialsMedium
Patrys raises A$3.2 million to advance injectable quetiapine clinical trials
20 Apr 2026 ·Capital Raising ·75
Patrys Advances Injectable Delirium Therapy Toward H2 2026 Clinical TrialsMedium
Patrys advances RLS-2201 manufacturing and FDA regulatory pathway for H2 2026 clinical trial
11 Mar 2026 ·Operational Update ·75
Patrys Secures $1.77M to Advance Deoxymab Platform Beyond OncologyMedium
Patrys raises $1.77M, advances deoxymab platform with preclinical studies, completes capital consolidation
30 Oct 2025 ·Quarterly Activities Report and Appendix 4C ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.